The DOI matches its Crossref record; 36 of the 39 references it cites were found in a registry or an index.
Comparative effectiveness of different treatment pathways for opioid use disorder.
Open accessAbstract
Importance: Although clinical trials demonstrate the superior effectiveness of medication for opioid use disorder (MOUD) compared with nonpharmacologic treatment, national data on the comparative effectiveness of real-world treatment pathways are lacking. Objective: To examine associations between opioid use disorder (OUD) treatment pathways and overdose and opioid-related acute care use as proxies for OUD recurrence. Design, Setting, and Participants: This retrospective comparative effectiveness research study assessed deidentified claims from the OptumLabs Data Warehouse from individuals aged 16 years or older with OUD and commercial or Medicare Advantage coverage. Opioid use disorder was identified based on 1 or more inpatient or 2 or more outpatient claims for OUD diagnosis codes within 3 months of each other; 1 or more claims for OUD plus diagnosis codes for opioid-related overdose, injection-related infection, or inpatient detoxification or residential services; or MOUD claims between January 1, 2015, and September 30, 2017. Data analysis was performed from April 1, 2018, to June 30, 2019. Exposures: One of 6 mutually exclusive treatment pathways, including (1) no treatment, (2) inpatient detoxification or residential services, (3) intensive behavioral health, (4) buprenorphine or methadone, (5) naltrexone, and (6) nonintensive behavioral health. Main Outcomes and Measures: Opioid-related overdose or serious acute care use during 3 and 12 months after initial treatment. Results: A total of 40 885 individuals with OUD (mean [SD] age, 47.73 [17.25] years; 22 172 [54.2%] male; 30 332 [74.2%] white) were identified. For OUD treatment, 24 258 (59.3%) received nonintensive behavioral health, 6455 (15.8%) received inpatient detoxification or residential services, 5123 (12.5%) received MOUD treatment with buprenorphine or methadone, 1970 (4.8%) received intensive behavioral health, and 963 (2.4%) received MOUD treatment with naltrexone. During 3-month follow-up, 707 participants (1.7%) experienced an overdose, and 773 (1.9%) had serious opioid-related acute care use. Only treatment with buprenorphine or methadone was associated with a reduced risk of overdose during 3-month (adjusted hazard ratio [AHR], 0.24; 95% CI, 0.14-0.41) and 12-month (AHR, 0.41; 95% CI, 0.31-0.55) follow-up. Treatment with buprenorphine or methadone was also associated with reduction in serious opioid-related acute care use during 3-month (AHR, 0.68; 95% CI, 0.47-0.99) and 12-month (AHR, 0.74; 95% CI, 0.58-0.95) follow-up. Conclusions and Relevance: Treatment with buprenorphine or methadone was associated with reductions in overdose and serious opioid-related acute care use compared with other treatments. Strategies to address the underuse of MOUD are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although data show that detoxification fails to reduce risk of relapse and overdose, we included it to reflect its real-world use.20”
From Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder (2023) · cites this paper as [20]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data
Quan, H., Sundararajan, V., Halfon, P., Fong, A., Burnand, B., Luthi, J.-C., Saunders, L. D., Beck, C. A., Feasby, T. E., & Ghali, W. A. (2005) · Medical Care · doi:10.1097/01.mlr.0000182534.19832.83 · Cited by 10,669
Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., Ferri, M., & Pastor-Barriuso, R. (2017) · BMJ · doi:10.1136/bmj.j1550 · Cited by 1,816
Drug and Opioid-Involved Overdose Deaths — United States, 2013–2017
Scholl, L., Seth, P., Kariisa, M., Wilson, N. O., & Baldwin, G. T. (2018) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm675152e1 · Cited by 1,754
Larochelle, M. R., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., Bagley, S. M., Liebschutz, J. M., & Walley, A. Y. (2018) · Annals of Internal Medicine · doi:10.7326/m17-3107 · Cited by 1,076
Self-citationLee, J. D., Nunes, E. V., Novo, P., Bachrach, K., Bailey, G. L., Bhatt, S., Farkas, S., Fishman, M., Gauthier, P., Hodgkins, C. C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32812-x · Cited by 700
Zibbell, J. E., Asher, A. K., Patel, R. C., Kupronis, B. A., Iqbal, K., Ward, J. W., & Holtzman, D. J. (2017) · American Journal of Public Health · doi:10.2105/ajph.2017.304132 · Cited by 699
The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis
Ciccarone, D. (2019) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2019.01.010 · Cited by 677
National and state treatment need and capacity for opioid agonist medication-assisted treatment
Jones, C. M., Campopiano, M., Baldwin, G., & McCance-Katz, E. (2015) · American Journal of Public Health · doi:10.2105/ajph.2015.302664 · Cited by 668
Weiss, R. D. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.121 · Cited by 540
Medications for Opioid Use Disorder Save Lives
Mancher, M., & Leshner, A. (2019) · National Academies Press eBooks · doi:10.17226/25310 · Cited by 473
Flagged first, then by citations
3 of the 39 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 801–900 of 995
Eckhardt, A. C., Waller, D. E., Shull, S., Lovejoy, T. I., Morasco, B. J., Gordon, A. J., & Wyse, J. J. B. (2024) · Substance Use & Addiction Journal · doi:10.1177/29767342241251761
10. Opioid Treatment in Primary Care Settings
Rozansky, H. A., & Samet, J. H. (2024) · American Public Health Association eBooks · doi:10.2105/9780875533452ch10
Feder, K. A., Li, Y., Burke, K. N., Byrne, L., Desai, I., Saloner, B. K., & Krawczyk, N. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4868534
El‐Sabawi, T., & Dineen, K. K. (2024) · The AMA Journal of Ethic · doi:10.1001/amajethics.2024.520
Emerson, R., Rogal, S. S., Bulls, H. W., Nugent, S. M., Anderson, A., Nash, S., Salay, M., Winstanley, E. L., Cameron, F. D. A., Demonte, W., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4877138
Sosnowski, D. W., Feder, K. A., Genberg, B. L., Mehta, S. H., & Kirk, G. D. (2024) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2024.111383
Chapter 54. Treatment of Substance Use Disorders
Sherman, B. J., Hartwell, K. J., McRae‐Clark, A. L., Herron, A., & Brady, K. T. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as54
Powers, J., Weyer, G. W., Conrad, R. C., Simon, K. M., & Bukstein, O. (2024) · Springer eBooks · doi:10.1007/978-3-031-54281-7_19
Lloyd, J., Treitler, P. C., Lister, J. J., Nowels, M., & Crystal, S. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209476
Li, W., Eisenberg, M. D., Song, M., Kennedy‐Hendricks, A., & Saloner, B. K. (2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001373
Bratu, M. L., Săndesc, D., Anghel, T., Bratosin, F., Vlad, S. V., Terzi, A., & Streian, C. G. (2024) · Life · doi:10.3390/life14101336
Borrelli, E. P., Saad, P., Barnes, N. E., Nelkin, H. D., Dumitru, D., & Lucaci, J. D. (2024) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s484831
Mehta, R., Dayan-Rosenman, D., Sellinger, D., & Tang, M. H. (2024) · NEJM Catalyst · doi:10.1056/cat.24.0082
Shaw, L. C., Hallowell, B. D., Paiva, T. J., Schulz, C. T., Daly, M. M., Borden, S. K., Goulet, J., Samuels, E. A., Cerdá, M., & Marshall, B. D. L. (2024) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001411
MOUD use among Hispanic clients increased post-ACA, yet differed by heritage and geographic location
Herrera, C., Choi, S., & Johnson, N. L. (2024) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2024.112509
A Narrative Review of Old and Emerging Treatment Modalities for Substance Use Disorders
Ahluwalia, T., Xu, X., Nelson, A., Gujral, I., Okafor, J., & Hubbard, M. R. (2024) · Cureus · doi:10.7759/cureus.75395
Síndrome de Abstinencia a los Opioides
Salazar, J. Z., Urrea, S. L., Tuirán, L. C. V., Solarte, D. M. E., Roldán, J. F. O., Ojeda, A. N. E., Motta, J. A. S., Guerrero, A. X. R., & García, O. A. B. (2024) · Ciencia Latina Revista Científica Multidisciplinar · doi:10.37811/cl_rcm.v8i6.15033
A Safer Way to Recovery Amidst the Toxic Drug Crisis
Klassen, S. (2024) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-024-01437-3
Ali, M. M., Taylor, E. A., Stein, B. D., Mizushima, Y., Agniel, D. M., & Cantor, J. (2025) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001439
Leveraging Real‐World Data to Address Potential Methadone Drug–Drug Interactions
Holstein, S. A. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3520
Special Issue on Substance Misuse and Addiction Disorders
Saucedo, C. (2025) · Western Journal of Emergency Medicine · doi:10.5811/westjem.41988
Noor, N. B., Pro, G. C., Acharya, M., Eswaran, H., & Hayes, C. J. (2025) · Addictive Behaviors Reports · doi:10.1016/j.abrep.2025.100588
Shah, K., Nameth, K., Choi, J., Burgette, L. F., & Osilla, K. C. (2025) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001464
Koutoujian, P. J., Bohler, R. M., Senst, T., Siddiqi, K., Rochani, H. D., & Kolodny, A. (2025) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2025.112616
H.B. 22-1326: Analysis of Colorado’s Fentanyl Policy
Morris, W. (2025) · doi:10.56902/etdcrp.2025.4
Reid, M. C., Harris, S. J., Grieb, S. M. D., Gattine, S., Lukco, Z., Hool, B., Aguirre, M., Fernández‐Aranda, F., Tomko, C. A., Whaley, S., et al. (2025) · Harm Reduction Journal · doi:10.1186/s12954-025-01172-5
Deng, H., Nikravesh, M., Raheemullah, A., & Tate, S. (2025) · Journal of Telemedicine and Telecare · doi:10.1177/1357633x251319851
Knudsen, H. K., Fallin‐Bennett, A., Fanucchi, L. C., Lofwall, M. R., McGladrey, M., Oser, C. B., Biggers, G., Ross, A., Chadwell, J., & WALSH, S. L. (2025) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001482
Englander, H. L., Rolland, B., & Jauffret‐Roustide, M. (2025) · Substance Use & Addiction Journal · doi:10.1177/29767342251324325
Dewey, J. M., Tompkins, J., Mericle, A. A., & Watson, D. P. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1519469
Rizwan, Z. M., Akhtar, H., Cunningham, J. L., Mara, K. C., O’Horo, J. C., Gajic, O., & Stevens, R. W. (2025) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2025.64
Kong, A., Long, V., Wang, E., Lau, A., & Moe, J. (2025) · Cureus · doi:10.7759/cureus.83593
Lawson, S., Hamilton, A., Lazarus, J., Jaffe, G. A., Li, E., Weinstein, L. C., Fidler, S. K., & Kelly, E. L. (2025) · Substance Use & Misuse · doi:10.1080/10826084.2025.2496931
Dow, P. M., George, M., Zullo, A. R., Ritter, A. Z., & Rahman, M. (2025) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001504
Lynch, S. T., Gordillo, V., Sacks, A., Groenendaal, E., Klepacz, L., Towey, E., & Ferrando, S. J. (2025) · Pharmacoepidemiology · doi:10.3390/pharma4020011
Substance Use & Systems Impact: A Mixed-Methods Community-Based Participatory Action Study
Dyett, J. (2024) · Scholars Archive - University at Albany (University at Albany, State University of New York) · doi:10.54014/knkz-qd6h
Medications for opioid use disorder shape immune responses during chronic HIV infection
Collora, J. A., Steinhauser, S. F., Davenport, T. C., Lin, D. C.-D., Eshetu, A., Zeidi, S., Kim, R., Frank, C. A., Kluger, Y., Springer, S. A., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102159
Emergency Department-Based Medication for Opioid Use Disorder: A 5-Year Experience
Seaberg, D. C., McKinnon, J., Haselton, L., Reuter, Q. R., Kolb, J., Vellanki, S., Morah, J. C., Oskvarek, J. J., & Jouriles, N. J. (2025) · Journal of the American College of Emergency Physicians Open · doi:10.1016/j.acepjo.2025.100192
Shulman, M., Hu, M., Sullivan, M. A., Greiner, M. G., Ohrtman, K., Opara, O., Nunes, E. V., & Bisaga, A. M. (2025) · American Journal on Addictions · doi:10.1111/ajad.70055
Beaulieu, É., & Rittenhouse, B. (2025) · Health Services and Outcomes Research Methodology · doi:10.1007/s10742-025-00349-6
Lim, J., Bruneau, J., Platt, R. W., & Panagiotoglou, D. (2025) · Drug Safety · doi:10.1007/s40264-025-01574-1
Assessing the impact of the introduction of generic methadone to the Ontario public drug formulary
Hamzat, B., Wang, T., Garg, R., Iacono, A., Tadrous, M., Wu, F., Wyman, J., Dodd, Z., Pinkerton, S., Smoke, A., et al. (2025) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2025.104918
You’ll Never Walk Alone: Multidisciplinary Teams for Drug-Use–Associated Infective Endocarditis
El-Dalati, S. A. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.07.002
Fitzgerald, M. M., Molfenter, T. D., Beck, S., Levine, M. F., Folland, A., & Madden, L. M. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5333580
Bórquez, A., Goldshear, J. L., Muñoz, S., Tornez, A., Vera, A., Medina‐Mora, M. E., Rangel, G., & Strathdee, S. A. (2025) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2025.101176 · Cited by 1
Truong, T. T. (2025) · doi:10.1093/med/9780197812631.003.0034
Owens, M. D., Adwell, A., Singh, S., Osilla, K. C., Tweedy, M., & Tsui, J. I. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-07132-4
Evaluation of a Medication for Opioid Use Disorder Initiation Program in the Emergency Department
Volney, J., MacEwan, S. R., Hefner, J. L., Teater, J. E., Kauffman, E., Gaughan, A. A., Olvera, R. G., & McAlearney, A. S. (2025) · Substance Use & Addiction Journal · doi:10.1177/29767342251355372
Titus-Glover, D., Unick, G. J., Zhu, S., Shim, S., Deng, Y., Gainers, J., & Shaya, F. T. (2025) · Substance Use & Addiction Journal · doi:10.1177/29767342251357676
Combined response to commentaries regarding Ivasiy et al. (2025)
Ivasiy, R., Madden, L. M., Johnson, K., Machavariani, E., Ahmad, B., Oliveros, D., Tan, J., Kil, N., & Altice, F. L. (2025) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2025.104935
Section 1115 Substance Use Disorder Waivers: Opportunities and Limitations
Statchen, T., Pollack, H. A., Abraham, A. J., Andrews, C. M., & Grogan, C. M. (2025) · Journal of Health Politics Policy and Law · doi:10.1215/03616878-12166733
Wallis, R., Allen, L., Davis, S. M., Linn, H., Ngo, A., Cai, Y., Speck, C., & Bias, T. K. (2025) · The Journal of Behavioral Health Services & Research · doi:10.1007/s11414-025-09956-0
Marlowe, D. B., Theiss, D. S., Pappacena, L., & Ostlie, E. M. (2025) · Criminal Justice Policy Review · doi:10.1177/08874034251363467
Parisi, A. B., Peacock, A. M., Krajewski, T., Paquette, C. E., & Brinkley‐Rubinstein, L. (2025) · Substance Use & Misuse · doi:10.1080/10826084.2025.2548939
Yaseliani, M., Jo, Y., Lindo, L., Faysal, J. A., & Hasan, M. M. (2025) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2025.209794
The Effect of Federal Policy Changes on Buprenorphine Prescribing in Massachusetts
Hayes, J. M., Cash, R. E., Ahmad, N. J., Menzies, J., Valerio, D. D., Dalvi, N., Young, L. D., & Weiner, S. G. (2025) · Journal of the American College of Emergency Physicians Open · doi:10.1016/j.acepjo.2025.100246
Ford, M. M., Nekkanti, S., Kusko, R. L., Paquin, Z. W., & Bodenberg, P. (2025) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2025.09.007
Schmutz, H. W., Willis, C., Duru, E. E., Guo, C., Velez, F. F., & Brixner, D. L. (2025) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/15360288.2025.2558745
Addiction Medicine for the General Practitioner
Canver, B. (2025) · Springer eBooks · doi:10.1007/978-3-031-93533-6_14
Scheidell, J. D., Frechette, J. M., Townsend, T., Zhou, Q., Manandhar-Sasaki, P., Fiellin, D. A., Heimer, R., Puglisi, L. B., Charles, D. L., Su, J. I.-S., et al. (2025) · BMC Public Health · doi:10.1186/s12889-025-24432-2
Yang, W.-T. (2025) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361251380642
Ketamine for addiction treatment
Dadiomov, D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29930-8.00012-6
Beyond MAT expansion: A mathematical modeling analysis of opioid use disorder intervention efficacy
Akram, M. Z., Blondino, C., & Wares, J. R. (2026) · Mathematical Biosciences · doi:10.1016/j.mbs.2026.109686
Canty, T., Sabounchi, N. S., Heimer, R., Pantalon, M. V., Ryus, C. R., Buchanan, L., Grewal, M., Maffei, J., D’Onofrio, G., & Heckmann, R. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-102796
Managing opioid withdrawal in the ED
Hearrell, A., & Quincy, B. L. (2025) · JAAPA · doi:10.1097/01.jaa.0000000000000283
Safe Prescribing Practices and Considerations of Opioids
Shah, S., Wandler, A. M., Miller, B. C., Ahmadzadeh, S., Shekoohi, S., & Kaye, A. D. (2025) · Springer eBooks · doi:10.1007/978-3-032-07407-2_15
Winiker, A. K., Jalisi, A., & Tobin, K. E. (2025) · Contemporary Drug Problems · doi:10.1177/00914509251394038
Best Practices for Buprenorphine Induction Strategies
Skarda, J. L., Sasser, R. M., Johnson, A. D., & Fogger, S. A. (2025) · International Journal of Addiction Nursing · doi:10.1097/jan.0000000000000670
Kedia, S., Schmidt, M., Entwistle, C., Ahuja, N. A., Mahmood, A., & Dillon, P. (2025) · Substance Use Research and Treatment · doi:10.1177/29768357251384774
Dickson‐Gómez, J., Tarima, S. S., Twaibu, W., Katende, D., Kyeswa, L., Glasman, L. R., Kiconco, A., Krechel, S., Johnston, B., Ogwal, M., et al. (2025) · AIDS and Behavior · doi:10.1007/s10461-025-04978-3
A modeling study of the opioid epidemic for vulnerable communities in Knoxville, TennesseePreprint
Eversman, K. K., Spannaus, A., Campbell, R. J., Pearcy, L. B., Trafton, J. A., Kapadia, A., & Strickland, C. (2025) · Research Square · doi:10.21203/rs.3.rs-8148367/v1
Truong, A. Q., Green, V. R., Moon, K. J., Agus, D., Bandara, S. N., & Heidari, O. (2025) · Social Science & Medicine · doi:10.1016/j.socscimed.2025.118868
Buprenorphine Dispensing Following Medicaid Expansion Amid Unwinding in North Carolina
Constantin, J., Chua, K., & McCullough, J. S. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.47933
Dhanoa, A., Viste, D., Rioux, W., Seo, B., Vasquez, M., VandenBerg, S., Anhorn, C., & Ghosh, S. M. (2025) · Addiction Science & Clinical Practice · doi:10.1186/s13722-025-00636-0
Chiosi, J. J., Mueller, P. P., Chhatwal, J., & Ciaranello, A. L. (2023) · Figshare · doi:10.6084/m9.figshare.23700557
Hartung, D. M., Markwardt, S., Johnston, K. A., Geddes, J., Baker, R., Leichtling, G. J., Hildebran, C., Chan, B., Cook, R. R., McCarty, D. W., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20521391
Jones, B. L. H., Geier, M., Neuhaus, J. M., Coffin, P. O., Snyder, H. R., Soran, C. S., Knight, K. R., & Suen, L. W. (2024) · Figshare · doi:10.6084/m9.figshare.25572589
Bailey, A., Harrington, C., & Evans, E. (2024) · Figshare · doi:10.6084/m9.figshare.26564649
Wyse, J. J. B., Mackey, K., Lovejoy, T. I., Kansagara, D. L., Tuepker, A., Gordon, A. J., Todd Korthuis, P., Herreid-O’Neill, A., Williams, B. E., & Morasco, B. J. (2022) · Figshare · doi:10.6084/m9.figshare.20110562
Crable, E. L., Grogan, C. M., Purtle, J., Roesch, S. C., & Aarons, G. A. (2024) · Figshare · doi:10.6084/m9.figshare.26569093
Additional file 1 of Reducing overdose deaths among persons with opioid use disorder in connecticut
Scheidell, J. D., Townsend, T., Zhou, Q., Manandhar-Sasaki, P., Rodriguez-Santana, R., Jenkins, M. G., Buchelli, M., Charles, D. L., Frechette, J. M., Su, J. I.-S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26726441
Ahmed, F. Z., Andraka‐Christou, B., Clark, M. H., Totaram, R., Atkins, D. N., & del Pozo, B. (2022) · Figshare · doi:10.6084/m9.figshare.20390784
Additional file 2 of Patient experiences of buprenorphine dispensing from a mobile medical unit
Messmer, S. E., Elmes, A. T., Infante, A. F., Patterson, A., Smith, M., Murphy, A. L., Jimenez, A. D., Mayer, S., Watson, D. P., Whitfield, K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26333430
Jones, B. L. H., Geier, M., Neuhaus, J. M., Coffin, P. O., Snyder, H. R., Soran, C. S., Knight, K. R., & Suen, L. W. (2024) · Figshare · doi:10.6084/m9.figshare.25572690
Clemans-Cope, L., Lynch, V., Payton, M., & Aarons, J. (2022) · Figshare · doi:10.6084/m9.figshare.20250430
Xu, K. Y., Gertner, A. K., Greenfield, S. F., Williams, A. R., & Grucza, R. A. (2024) · Figshare · doi:10.6084/m9.figshare.26694297
Cook, R. R., Foot, C. A., Arah, O. A., Humphreys, K., Rudolph, K. E., Luo, S. X., Tsui, J. I., Levander, X. A., & Korthuis, P. T. (2023) · Figshare · doi:10.6084/m9.figshare.22607152
Additional file 1 of Patient experiences of buprenorphine dispensing from a mobile medical unit
Messmer, S. E., Elmes, A. T., Infante, A. F., Patterson, A., Smith, M., Murphy, A. L., Jimenez, A. D., Mayer, S., Watson, D. P., Whitfield, K., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26333291
Andraka‐Christou, B., Randall-Kosich, O., Golan, M., Totaram, R., Saloner, B. K., Gordon, A. J., & Stein, B. D. (2022) · Figshare · doi:10.6084/m9.figshare.19498236
Moon, K. J., Bryant, I., Trinh, A., Hasenstab, K. A., Carter, B., Barclay, R., & Nawaz, S. (2024) · Figshare · doi:10.6084/m9.figshare.26607292
Andraka‐Christou, B., Randall-Kosich, O., Golan, M., Totaram, R., Saloner, B. K., Gordon, A. J., & Stein, B. D. (2022) · Figshare · doi:10.6084/m9.figshare.19498239
Opioids in clinical practice: From punitive to partnership
Sparkls, E. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-26504-4.00015-6
Ellis, S., Witzig, J., Basaldu, D., Rudd, B. N., Gastala, N., Tabachnick, A. R., Kang, S., Henry, T., Stackhouse, N., & Wardle, M. C. (2025) · Addiction Science & Clinical Practice · doi:10.1186/s13722-025-00621-7
Rossi, E., Waterman, R. W., Chorny, Y., Ahmed, S., & Remers, S. (2025) · The Canadian Journal of Addiction · doi:10.1097/cxa.0000000000000253
London, E. D., Dean, A. C., Garza, R. D. L., Lachoff, H., Mooney, L. J., Torrington, M., Whelan, F., McClintick, M. N., Ghahremani, D. G., Elezi, G., et al. (2025) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001640
Carroll, J. J., Salemi, A., Ostrach, B. M. M., El‐Sabawi, T., Morrissey, B., Dixon, S. K., & Saucier, R. (2026) · Substance Use & Misuse · doi:10.1080/10826084.2025.2611422
Risk of opioid overdose during buprenorphine treatment for opioid use disorder in the fentanyl era
Chambers, L. C., Hallowell, B. D., Zullo, A., Rodríguez, M., Khan, M. A., Berk, J., Gaither, R., Daly, M., Wightman, R., & Beaudoin, F. L. (2026) · Addictive Behaviors · doi:10.1016/j.addbeh.2026.108603
Metadata
- Authors
- Wakeman, S. E., Larochelle, M. R., Ameli, O., Chaisson, C. E., McPheeters, J. T., Crown, W. H., Azocar, F., & Sanghavi, D. M.
- Affiliations
- Harvard University (US)
- Boston University (US)
- Integrated Programs, OptumLabs Inc, Cambridge, Massachusetts
- Optum (United States) (US)
- Department of Research, OptumLabs, Cambridge, Massachusetts
- Department of Research, Optum Behavioral Health, Cambridge, Massachusetts
- UnitedHealth Group (United States) (US)
- Corresponding author
- Wakeman, Sarah E.
- ORCID
- Venue
- JAMA Network Open
- Publisher
- American Medical Association (AMA)
- Published
- 2020-02-05
- Volume
- 3
- Issue
- 2
- Pages
- e1920622
- ISSN
- 2574-3805 (ISSN-L)
- PMC
- PMC11143463
- OpenAlex
- W3005454586
- Cited by
- 995
- References
- 39
- Citations by year
- 2026: 137 · 2025: 170 · 2024: 192 · 2023: 161 · 2022: 158 · 2021: 128 · 2020: 49
- FWCI
- 92.82
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- JAMA Network Open (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Massachusetts General Hospital
- School of Medicine, Boston University (1UL1TR001430)
- Laura and John Arnold Foundation
- Office of National Drug Control Policy (G1799ONDCP06B)
- Hamilton Health Sciences Foundation
- National Institutes of Health (UL1TR001430)
- Centers for Disease Control and Prevention (U01CE002780)
- U.S. Food and Drug Administration (HHSF223200910006I)
- Substance Abuse and Mental Health Services Administration (1H79TI081442-01)
- National Institute on Drug Abuse (K23DA042168, R01DA044526, UG1DA015831, G1799ONDCP06B)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- opioid use disorder, medication-assisted treatment, buprenorphine, methadone, naltrexone, inpatient detoxification, residential treatment, opioid overdose, acute care utilization, treatment pathways, comparative effectiveness, real-world evidence, injection-related infections
- MeSH terms
- Adolescent, Adult, Analgesics, Opioid, Behavior Therapy, Buprenorphine, Female, Humans, Male, Methadone, Middle Aged, Opioid-Related Disorders, Retrospective Studies, United States, Proportional Hazards Models, Substance Abuse Treatment Centers, Treatment Outcome, Critical Pathways, Young Adult, Comparative Effectiveness Research, Opiate Substitution Treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
